Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

May 19, 2023 0

Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization …

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

May 18, 2023 0

Prostate Cancer Prostate cancer is the most common type of cancer found in men, accounting for …

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI

May 15, 2023 0

Celldex Therapeutics Announcement Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with …

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

May 9, 2023 0

Longeveron in the NEWS On May 9, 2023, Longeveron (LGVN) announced new long-term follow-up data from …

Why CureVac Stock Traded Up in a Bad Day Market

May 8, 2023 0

CureVac B.V. CureVac (CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) …

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV

May 4, 2023 0

Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex® Today, May 4, 2023, Gilead Sciences (GILD) acknowledged …

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

May 1, 2023 0

May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The …

ImmunoGen’s Obvious Recent Progress

April 28, 2023 0

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results On April 28, 2023, ImmunoGen (IMGN) reviewed …

Vertex Receives CHMP Positive Opinion for ORKAMBI in Children with Cystic Fibrosis Aged 1 – >2 Years

April 27, 2023 0

Vertex Pharmaceuticals ORKAMBI Receives Positive CHMP Opinion Today, April 27, Vertex Pharmaceuticals (VRTX) announced that the …

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

April 25, 2023 0

Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir Atea Pharmaceuticals (AVIR) announced that the U.S. FDA …

Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

April 21, 2023 0

Apellis Pharmaceuticals Validation for Pegcetacoplan Apellis Pharmaceuticals (APLS) announced the receival of validation of its marketing applications …

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

April 21, 2023 0

Important News from CymaBay Therapeutics Primary Biliary Cholangitis Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that …

Important News from Novartis MS Product Kesimpta®

April 20, 2023 0

From Novartis on April 20, 2023 The ALITHIOS open-label extension study demonstrated that continuous treatment with …

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

April 19, 2023 0

News from Innoviva That We Consider Positively Impacting and Extremely Important Innoviva, Inc. (INVA) (Innoviva), announced …

Why the FDA Accepted to Review Merck’s KEYTRUDA (sBLA) for The Treatment of HER2 Negative Gastric Adenocarcinoma

April 14, 2023 0

Merck in the NEWS Merck (MRK) announced that the U.S. FDA has accepted for review a …

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

April 12, 2023 0

Sanofi Commercial Control of Beyfortus Against RSV In the morning, we promised to tell our readers …

Regenxbio Receives FDA Fast Track Designation for RGX-202 for the Treatment of Duchenne Muscular Dystrophy

April 11, 2023 0

Regenxbio in the NEWS Today, the U.S. FDA granted Fast Track designation for Regenxbio (RGNX) Gene therapy …

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

April 3, 2023 0

Vertex Pharmaceuticals and CRISPR Therapeutics Completion of BLAs Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced …

TG Therapeutics Announced Positive CHMP Opinion of BRIUMVI for Relapsing Forms of MS in Adults